Bone Biologics Completes $5.75 Million Funding Round

By Julie A. Vetalice

Bone Biologics completed a US $5.75MM funding round with participation from Musculoskeletal Transplant Foundation, Orthofix and Hankey Capital. Proceeds will support development and synthesis of a potential bone graft substitute, with an initial focus on spinal fusion applications.

Source: Bone Biologics

Bone Biologics developed Nell-1™ bone growth factor as a lower-cost alternative to current growth factor products.

In late 2Q15, Biologics completed a $2MM funding round intended to support preparation for human clinical trials to validate the technology.

Product Labels: Bone Graft Materials/DBM, Spinal Fusion

Tags: Funding